![Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion | Business Wire Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion | Business Wire](https://mms.businesswire.com/media/20200727005023/en/736961/23/Aerie_Logo_Updated__July_2019.jpg)
Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion | Business Wire
![BlogWell Chicago Social Media Case Study: American Eagle Outfitters, presented by Jamie Simoni | PPT BlogWell Chicago Social Media Case Study: American Eagle Outfitters, presented by Jamie Simoni | PPT](https://cdn.slidesharecdn.com/ss_thumbnails/bw24chipresentation-aeo-130710142300-phpapp01-thumbnail.jpg?width=640&height=640&fit=bounds)
BlogWell Chicago Social Media Case Study: American Eagle Outfitters, presented by Jamie Simoni | PPT
![Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.](https://www.sec.gov/Archives/edgar/data/1337553/000119312520264340/g91227ex99_1s3g1.jpg)
Aerie Pharmaceuticals Inc - For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares.
![Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant | Business Wire Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant | Business Wire](https://mms.businesswire.com/media/20190425005174/en/701134/22/Aerie_PI_Logo.jpg)